Moderna COVID-19 Vaccine Retains Neutralizing Activity Against Emerging Variants First Identified in the U.K. and the Republic of South Africa | Moderna, Inc.

Out of an abundance of caution, Moderna launches clinical program to boost immunity to emerging variants Manuscript posted to preprint server; company to host conference call once manuscript is available CAMBRIDGE, Mass. –(BUSINESS WIRE)–Jan. 25, 2021– Moderna Inc .

Read the full article here

Related Articles